ID   Calu-3
AC   CVCL_0609
SY   CaLu-3; CALU-3; Calu 3; Calu3; CALU3
DR   BTO; BTO:0002750
DR   CLO; CLO_0002192
DR   EFO; EFO_0002819
DR   CLDB; cl634
DR   CLDB; cl635
DR   CLDB; cl5176
DR   Abcam; ab275465
DR   AddexBio; C0016001/30
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BCRJ; 0264
DR   BioSample; SAMN03471552
DR   BioSample; SAMN10988517
DR   cancercelllines; CVCL_0609
DR   CCRID; 1101HUM-PUMC000032
DR   CCRID; 1101HUM-PUMC000329
DR   CCRID; 3101HUMTCHu157
DR   CCRID; 4201HUM-CCTCC00647
DR   Cell_Model_Passport; SIDM00922
DR   ChEMBL-Cells; CHEMBL3307390
DR   ChEMBL-Targets; CHEMBL614534
DR   CLS; 305032
DR   Cosmic; 687777
DR   Cosmic; 910562
DR   Cosmic; 933578
DR   Cosmic; 945227
DR   Cosmic; 961842
DR   Cosmic; 1006532
DR   Cosmic; 1028940
DR   Cosmic; 1146873
DR   Cosmic; 1219068
DR   Cosmic; 1239869
DR   Cosmic; 1434969
DR   Cosmic; 1802295
DR   Cosmic; 2125219
DR   Cosmic; 2664117
DR   Cosmic; 2772161
DR   Cosmic-CLP; 687777
DR   DepMap; ACH-000392
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GDSC; 687777
DR   GEO; GSM159355
DR   GEO; GSM159356
DR   GEO; GSM159357
DR   GEO; GSM159358
DR   GEO; GSM253347
DR   GEO; GSM353233
DR   GEO; GSM434276
DR   GEO; GSM513948
DR   GEO; GSM514318
DR   GEO; GSM784249
DR   GEO; GSM794262
DR   GEO; GSM827549
DR   GEO; GSM886915
DR   GEO; GSM887981
DR   GEO; GSM1374433
DR   GEO; GSM1374434
DR   GEO; GSM1669658
DR   IARC_TP53; 21264
DR   IGRhCellID; Calu3
DR   KCLB; 30055
DR   LiGeA; CCLE_462
DR   LINCS_HMS; 50010
DR   Lonza; 342
DR   MetaboLights; MTBLS762
DR   MetaboLights; MTBLS2840
DR   PharmacoDB; Calu3_179_2019
DR   PRIDE; PXD000589
DR   PRIDE; PRD000594
DR   PRIDE; PXD019645
DR   PRIDE; PXD023418
DR   PRIDE; PXD023422
DR   PRIDE; PXD023760
DR   PRIDE; PXD024242
DR   PRIDE; PXD024375
DR   PRIDE; PXD024883
DR   PRIDE; PXD025499
DR   PRIDE; PXD026302
DR   PRIDE; PXD030304
DR   PRIDE; PXD034135
DR   Progenetix; CVCL_0609
DR   PubChem_Cell_line; CVCL_0609
DR   TOKU-E; 768
DR   Wikidata; Q52392355
RX   PubMed=327080;
RX   PubMed=3129183;
RX   PubMed=3335022;
RX   PubMed=3518877;
RX   PubMed=3940644;
RX   PubMed=6220172;
RX   PubMed=7459858;
RX   PubMed=7515578;
RX   PubMed=9636188;
RX   PubMed=10523844;
RX   PubMed=11064206;
RX   PubMed=15463957;
RX   PubMed=17483357;
RX   PubMed=18083107;
RX   PubMed=19153074;
RX   PubMed=19472407;
RX   PubMed=20090954;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20557307;
RX   PubMed=22460905;
RX   PubMed=22961666;
RX   PubMed=24207061;
RX   PubMed=25485619;
RX   PubMed=25555374;
RX   PubMed=25877200;
RX   PubMed=25894527;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29681454;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=34339474;
RX   PubMed=35839778;
RX   PubMed=35879413;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-533.
CC   Population: Caucasian.
CC   Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474).
CC   Doubling time: 35 hours (Note=In RPMI 1640 + 10% FBS), 45 hours (Note=In ACL-3), 37 hours (Note=In ACL-3+BSA) (PubMed=3940644); 40.1 hours (PubMed=29681454); ~84 hours (PubMed=34339474).
CC   HLA typing: A*24:02,68:01; B*07:02,51:01; C*15:02,15:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (PubMed=20557307; ATCC).
CC   Omics: Array-based CGH.
CC   Omics: Cell surface proteome.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.63%; Native American=0%; East Asian, North=2.09%; East Asian, South=0%; South Asian=0%; European, North=67.76%; European, South=29.51% (PubMed=30894373).
CC   Misspelling: CALV3; Cosmic=1434969.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): AddexBio; ATCC; CCRID; Cosmic-CLP; KCLB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 12,14
ST   D18S51: 14,17
ST   D19S433: 12,13
ST   D21S11: 28,30
ST   D2S1338: 19
ST   D3S1358: 15,18
ST   D5S818: 11
ST   D7S820: 10,11
ST   D8S1179: 11,15
ST   FGA: 25
ST   Penta D: 9,16
ST   Penta E: 5,21
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   25Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 42
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
RX   PubMed=3129183;
RA   Hubbard W.C., Alley M.C., McLemore T.L., Boyd M.R.;
RT   "Evidence for thromboxane biosynthesis in established cell lines
RT   derived from human lung adenocarcinomas.";
RL   Cancer Res. 48:2674-2677(1988).
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=3940644;
RA   Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.;
RT   "Growth of cell lines and clinical specimens of human non-small cell
RT   lung cancer in a serum-free defined medium.";
RL   Cancer Res. 46:798-806(1986).
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
RX   PubMed=7515578; DOI=10.1152/ajplung.1994.266.5.L493;
RA   Shen B.Q., Finkbeiner W.E., Wine J.J., Mrsny R.J., Widdicombe J.H.;
RT   "Calu-3: a human airway epithelial cell line that shows cAMP-dependent
RT   Cl-secretion.";
RL   Am. J. Physiol. 266:L493-L501(1994).
RX   PubMed=9636188; DOI=10.1073/pnas.95.13.7556;
RA   Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M.,
RA   Old L.J., Schreiber R.D.;
RT   "Demonstration of an interferon gamma-dependent tumor surveillance
RT   system in immunocompetent mice.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:7556-7561(1998).
RX   PubMed=10523844; DOI=10.1038/sj.onc.1202957;
RA   Agochiya M., Brunton V.G., Owens D.W., Parkinson E.K., Paraskeva C.,
RA   Keith W.N., Frame M.C.;
RT   "Increased dosage and amplification of the focal adhesion kinase gene
RT   in human cancer cells.";
RL   Oncogene 18:5646-5653(1999).
RX   PubMed=11064206; DOI=10.1016/S0378-5173(00)00452-X;
RA   Foster K.A., Avery M.L., Yazdanian M., Audus K.L.;
RT   "Characterization of the Calu-3 cell line as a tool to screen
RT   pulmonary drug delivery.";
RL   Int. J. Pharm. 208:1-11(2000).
RX   PubMed=15463957; DOI=10.1016/j.jcf.2004.05.040;
RA   Gruenert D.C., Willems M., Cassiman J.-J., Frizzell R.A.;
RT   "Established cell lines used in cystic fibrosis research.";
RL   J. Cyst. Fibros. 3:191-196(2004).
RX   PubMed=17483357; DOI=10.1158/0008-5472.CAN-06-4495;
RA   Tooker P., Yen W.-C., Ng S.-C., Negro-Vilar A., Hermann T.W.;
RT   "Bexarotene (LGD1069, Targretin), a selective retinoid X receptor
RT   agonist, prevents and reverses gemcitabine resistance in NSCLC cells
RT   by modulating gene amplification.";
RL   Cancer Res. 67:4425-4433(2007).
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H.,
RA   Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P.,
RA   Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.-M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q.,
RA   Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RX   PubMed=19153074; DOI=10.1093/hmg/ddp034;
RA   Medina P.P., Castillo S.D., Blanco S., Sanz-Garcia M., Largo C.,
RA   Alvarez S., Yokota J., Gonzalez-Neira A., Benitez J., Clevers H.C.,
RA   Cigudosa J.C., Lazo P.A., Sanchez-Cespedes M.;
RT   "The SRY-HMG box gene, SOX4, is a target of gene amplification at
RT   chromosome 6p in lung cancer.";
RL   Hum. Mol. Genet. 18:1343-1352(2009).
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
RX   PubMed=20090954; DOI=10.1371/journal.pone.0008729;
RA   Yoshikawa T., Hill T.E., Yoshikawa N., Popov V.L., Galindo C.L.,
RA   Garner H.R., Peters C.J., Tseng C.-T.;
RT   "Dynamic innate immune responses of human bronchial epithelial cells
RT   to severe acute respiratory syndrome-associated coronavirus
RT   infection.";
RL   PLoS ONE 5:E8729-E8729(2010).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
RX   PubMed=24207061; DOI=10.1186/1559-0275-10-16;
RA   Cerciello F., Choi M., Nicastri A., Bausch-Fluck D., Ziegler A.,
RA   Vitek O., Felley-Bosco E., Stahel R.A., Aebersold R., Wollscheid B.;
RT   "Identification of a seven glycopeptide signature for malignant
RT   pleural mesothelioma in human serum by selected reaction monitoring.";
RL   Clin. Proteomics 10:16.1-16.12(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25555374; DOI=10.1016/j.ejps.2014.12.017;
RA   Kreft M.E., Jerman U.D., Lasic E., Hevir-Kene N., Rizner T.L.,
RA   Peternel L., Kristan K.;
RT   "The characterization of the human cell line Calu-3 under different
RT   culture conditions and its use as an optimized in vitro model to
RT   investigate bronchial epithelial function.";
RL   Eur. J. Pharm. Sci. 69:1-9(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., Deberardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=34339474; DOI=10.1371/journal.pone.0255622;
RA   Pommerenke C., Rand U., Uphoff C.C., Nagel S., Zaborski M., Hauer V.,
RA   Kaufmann M., Meyer C., Denkmann S.A., Riese P., Eschke K., Kim Y.,
RA   Safranko Z.M., Kurolt I.-C., Markotic A., Cicin-Sain L., Steenpass L.;
RT   "Identification of cell lines CL-14, CL-40 and CAL-51 as suitable
RT   models for SARS-CoV-2 infection studies.";
RL   PLoS ONE 16:E0255622-E0255622(2021).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
RX   PubMed=35879413; DOI=10.1038/s41588-022-01110-2;
RA   Rebendenne A., Roy P., Bonaventure B., Chaves Valadao A.L.,
RA   Desmarets L., Arnaud-Arnould M., Rouille Y., Tauziet M.,
RA   Giovannini D., Touhami J., Lee Y., DeWeirdt P., Hegde M., Urbach S.,
RA   Koulali K.E., de Gracia F.G., McKellar J., Dubuisson J., Wencker M.,
RA   Belouzard S., Moncorge O., Doench J.G., Goujon C.;
RT   "Bidirectional genome-wide CRISPR screens reveal host factors
RT   regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs.";
RL   Nat. Genet. 54:1090-1102(2022).